| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $33.5M | +1169.2% |
| Cost of Revenue | $190K | -6.9% |
| R&D Expense | $58.2M | +35.9% |
| SG&A Expense | $26.9M | +12.5% |
| Operating Income | -$51.8M | +19.4% |
| Income Tax | $0 | — |
| Net Income | -$52.7M | +13.6% |
| EPS (Basic) | -$1.11 | +33.1% |
| EPS (Diluted) | -$1.11 | +33.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $34.7M | +55.8% |
| Short-term Investments | $71.8M | +61.2% |
| Accounts Receivable | $95K | +3.3% |
| Inventory | $310K | +79.2% |
| Current Assets | $107.9M | +56.0% |
| Total Assets | $114.9M | +50.8% |
| Current Liabilities | $16.7M | +3.3% |
| Long-term Debt |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$49.0M | +3.2% |
| Capital Expenditures | $489K | +69.2% |
| Investing Cash Flow | -$26.9M | -305.8% |
| Financing Cash Flow | $88.3M | +202.8% |
| Free Cash Flow | -$49.5M | +2.7% |
| $15.0M |
| +0.0% |
| Total Liabilities | $51.5M | +19.1% |
| Stockholders' Equity | $53.6M | +62.5% |